A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Bexagliflozin in Subjects With Type 2 Diabetes Mellitus Who Are Not Adequately Controlled by Metformin Alone
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Jul 2018
At a glance
- Drugs Bexagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Theracos
- 31 Aug 2018 Biomarkers information updated
- 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 23 May 2018 Planned End Date changed from 1 Oct 2019 to 1 Jan 2019.